Henry Schein (NASDAQ:HSIC) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Henry Schein (NASDAQ:HSIC) issued its earnings results on Tuesday. The company reported $1.27 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.03, FiscalAI reports. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The business had revenue of $3.46 billion for the quarter, compared to analyst estimates of $3.37 billion. During the same period last year, the company posted $1.10 EPS. The business’s quarterly revenue was up 6.7% on a year-over-year basis. Henry Schein updated its FY 2026 guidance to 5.290-5.390 EPS.

Here are the key takeaways from Henry Schein’s conference call:

• Strong second-quarter performance: Global sales rose 6.7% to $3.5 billion, while non-GAAP operating income increased 10.5% and non-GAAP EPS grew 15.5% to $1.27, supported by 25 basis points of operating-margin expansion.
• Henry Schein raised its 2026 outlook, now expecting sales growth of 4.5%–5.5% and non-GAAP EPS of $5.29–$5.39, or 6%–8% growth. Management cited sustained sales momentum and stronger underlying performance, though the outlook excludes further remeasurement gains.
• The company remains on track for more than $200 million in operating-income improvements from its value-creation program, including a $125 million run-rate by year-end 2026; outsourcing, procurement consolidation, and pricing initiatives are beginning to contribute.
• Henry Schein One continued to post strong growth, with nearly 13,000 Dentrix Ascend and Dentally cloud customers and approximately 90% recurring revenue. AI-enabled clinical and practice-management tools are driving upgrades to higher-value packages and could increase customer retention and share of wallet.
• Growth was uneven across markets: U.S. dental merchandise and international businesses gained momentum, while U.S. dental equipment faced difficult comparisons and medical sales remained pressured by lower point-of-care diagnostic demand. Management expects U.S. equipment growth in the second half, but acknowledged that higher-margin specialty and technology mix benefits may be partly offset by equipment sales.

Henry Schein Trading Up 4.7%

NASDAQ:HSIC opened at $90.56 on Tuesday. The business’s 50-day moving average is $82.44 and its two-hundred day moving average is $78.38. The firm has a market capitalization of $10.32 billion, a PE ratio of 27.18, a price-to-earnings-growth ratio of 1.65 and a beta of 0.80. Henry Schein has a 12 month low of $61.94 and a 12 month high of $91.98. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.36 and a quick ratio of 0.75.

Insider Buying and Selling at Henry Schein

In related news, Director William K. Daniel bought 10,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $69.19 per share, with a total value of $691,900.00. Following the completion of the transaction, the director directly owned 20,000 shares of the company’s stock, valued at approximately $1,383,800. This represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.89% of the stock is owned by insiders.

Hedge Funds Weigh In On Henry Schein

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. CYBER HORNET ETFs LLC purchased a new position in Henry Schein in the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc acquired a new stake in Henry Schein in the second quarter valued at approximately $27,000. Federated Hermes Inc. purchased a new stake in shares of Henry Schein during the fourth quarter valued at approximately $32,000. Los Angeles Capital Management LLC purchased a new stake in shares of Henry Schein during the fourth quarter valued at approximately $37,000. Finally, Palisade Asset Management LLC acquired a new position in shares of Henry Schein during the third quarter worth $100,000. 96.62% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have commented on HSIC. Citigroup began coverage on Henry Schein in a report on Wednesday, April 15th. They issued a “buy” rating and a $100.00 price objective on the stock. BMO Capital Markets started coverage on Henry Schein in a report on Wednesday, July 8th. They set a “market perform” rating and a $85.00 target price for the company. Mizuho dropped their target price on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Morgan Stanley restated an “underweight” rating and issued a $64.00 price target (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. Finally, UBS Group reaffirmed a “neutral” rating and set a $89.00 price target (up from $85.00) on shares of Henry Schein in a research report on Tuesday, July 28th. Eight equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $89.36.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.